Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation

Experimental Hematology

Volumn 31, Issue 7, 2003, Pages 559-566

  Tabbara, Imad A ^a   Ingram, Richard M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; PACLITAXEL; PENTOSTATIN; PURINE DERIVATIVE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOTRANSPLANTATION; ALOPECIA; AUTOTRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG FATALITY; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERMETHOD COMPARISON; ISOGRAFT; KIDNEY CARCINOMA; LEUKEMIA; LIVER VEIN OBSTRUCTION; LOW ENERGY RADIATION; LYMPHOCYTOPENIA; LYMPHOMA; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NEUTROPENIA; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK; SIDE EFFECT; T LYMPHOCYTE; TUMOR CELL; WHOLE BODY RADIATION;

EID: 0038722146     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00071-7     Document Type: Article

References (96)

1. Thomas E.D., Blume K.G., Forman S.J., et al. Hematopoietic Cell Transplantation. 2nd ed: 1999;Blackwell Science, Boston.
2. Armitage J.O. Bone marrow transplantation. N Engl J Med. 330:1994;827-838.
3. Molina A.J., Storb R.F. Hematopoietic stem cell transplantation in older adults. Rowe J.M., Lozams H.M., Carella A.M. Handbook of Bone Marrow Transplantation. 1st ed. 2000;111-137 Martin Dunitz Ltd, London.
4. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 300:1979;1068-1073.
5. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D., The Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 304:1981;1529-1533.
6. Kersy J.H., Weisdorf D., Nesbit M.E., et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med. 317:1987;1618-1624.
7. Fefer A., Sullivan K.M., Weiden P., et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res. 244:1987;401-408.
8. Gale R.P., Horowitz M.M., Ash R.C., et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 120:1994;646-652.
9. Nimer S.D., Giorgi J., Gajewski J.L., et al. Selective depletion of CD8+ cells for prevention of graft-versus host disease after bone marrow transplantation: a randomized controlled trial. Transplantation. 57:1994;82-87.
10. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 73:1989;1720-1728.
11. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:1995;2041-2050.
12. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 23:1995;1553-1562.
13. Slavin S., Ackerstein A., Morecki S., et al. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant. 28:2001;795-798.
14. Slavin S., Weiss L., Morecki S., et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 11:1981;155-158.
15. Slavin S., Nagler A. New developments in bone marrow transplantation. Curr Opin Oncol. 3:1991;254-271.
16. Shimoni A., Anderlini P., Andersson B., et al. CD8-depleted donor lymphocyte infusion (DLI) for the treatment of CML relapse after allogeneic transplant: long term follow up and factors predicting outcome. Blood. 94:1999;700a.
17. Kolb H.J., Mittermuller J., Clemm C.H., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
18. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 86:1995;1261-1268.
19. Apperley J.F., Mauro F.R., Goldman J.M., et al. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft-versus-leukemia effect. Br J Hematol. 69:1988;239-245.
20. Giralt S., Gajewski J., Khouri I., et al. Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia. Blood. 90:(suppl 1):1997;1857a.
21. Van Besien K., Sobocinski K., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 92:1998;1832-1836.
22. Collins R.H. Jr., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 15:1997;433-444.
23. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 320:1989;828-834.
24. Porter D.L., Collinis R.H. Jr., Hardy C., et al. Treatment of relapsed leuke-mia after unrelated donor marrow transplantation with unrelateddonor leukocyte infusions. Blood. 95:2000;1214-1221.
25. Van Besien K.W., De Lima M., Giralt S.A., et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 19:1997;977-982.
26. Lenine J.E., Braun T., Penza S.l., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 20:2002;405-412.
27. Collins R.H., Goldstein S., Giralt S., et al. Donor leukocyte infusionsin acute lymphocytic leukemia. Bone Marrow Transplant. 26:2000;511-516.
28. Burchenal J.H., Oettengen H.F., Holmberg E.A.D., Hemphill S.C., Reppert J.A. Effect of total body irradiation on the transplantability of mouse leukemias. Cancer Res. 20:1960;425-430.
29. Thomas E.D., Storb R., Clift R.A., et al. Bone marrow transplantation. N Engl J Med. 292:1975;832-843. 895-902.
30. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 6:2000;1018-1023.
31. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 86:1995;1261-1268.
32. Sykes M., Strober S. Mechanisms of tolerance. Thomas E.d., Blume K.G., Forman S.J. Hematopoietic Cell Transplantation. 2nd ed. 1999;264-286 Blackwell Science, Boston.
33. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 83:1998;904-909.
34. Sandmaier B.M., McSweeney P., Yu C., Storb R. Non-myeloablative transplants: preclinical and clinical results. Semin Oncol. 27:(suppl 5):2000;78-81.
35. Feinstein L., Storb R. Non-myeloablative hematopoietic cell transplantation. Curr Opin Oncol. 13:2001;95-100.
36. Spitzer T.R., McAfee S., Sackstein R., et al. Intentional induction of mixed chimerism and achievement of antitumor responses after non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 6:2000;309-320.
37. Maris M., Niederwieser D., Sandmaier B., et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood. 98:2001;858a.
38. McSweeney P.A., Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant. 5:1999;192-203.
39. Sandmaier B., Maloney D., Gooley T., et al. Nonmyeloablative hematopoietic stem cell transplant (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood. 98:2001;742a-743a.
40. Storb R., Yu C., McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. Thomas E.D., Blume K.G., Forman S.J. Hematopoietic Cell Transplantation. 2nd ed. 1999;287-295 Blackwell Science, Boston.
41. Chao N.J. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant. 3:1997;1-10.
42. Solheim J.C. Class I MHC molecules: assembly and antigen presentation. Immunol Rev. 172:1999;11-19.
43. Pieters J. MHC class II-restricted antigen processing and presentation. Adv Immunol. 75:2000;159-208.
44. Gambacorti-Passerini C., Bertazzoli C., Dermime S., Scardino A., Schendel D., Parmiani G. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. Clin Cancer Res. 3:1997;675-683.
45. Molldrem J.J., Lee P.P., Wang C.Q., Champlin R.E., Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:1999;2675-2681.
46. Bocchia M., Korontsvit T., Xu Q., et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 97:1996;3587-3592.
47. Van Elsas A., Nijman H.W., Van der Minne C.E., et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer. 61:1995;389-396.
48. Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 95:2000;286-293.
49. Oka Y., Elisseeva O.A., Tsuboi A., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 51:2000;99-107.
50. Molldrem J., Dermime S., Parker K., et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 88:1996;2450-2457.
51. Molldrem J.J., Clave E., Jiang Y.Z., et al. Cytotoxic T lymphocytes specific for a non-polymorphic proteinase 3 peptide preferentially in-hibit chronic myeloid leukemia colony-forming units. Blood. 90:1997;2529-2534.
52. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Imunol Rev. 157:1997;125-140.
53. Warren E.H., Greenberg P.D., Riddell S.R. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 91:1998;2197-2207.
54. Warren E.H., Gaven M., Greenberg P.D., Riddell S.R. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol. 5:1998;429-433.
55. van der Harst D., Goulmy E., Falkenburg J.H., et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 83:1994;1060-1066.
56. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as post remission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 91:1998;1083-1090.
57. Bergmann L., Maurer U., Weidmann E. Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma. 25:1997;435-443.
58. Gao L., Bellantuono I., Elsasser A., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 95:2000;2198-2203.
59. den Haan J.M., Sherman N.E., Blokland E., et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 268:1995;1476-1480.
60. Dolstra H., Fredrix H., Maas F., et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 189:1999;301-308.
61. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 94:1999;333-339.
62. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 87:1996;2195-2204.
63. Wu C.J., Yang X.F., McLaughlin S., et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 106:2000;705-714.
64. Yonemoto R.H., Terasaki P.I. Cancer immunotherapy with HLA-compatible thoracic duct lymphocyte transplantation: a preliminary report. Cancer. 30:1972;1438-1443.
65. Porter D.L., Rolth M.S., McGarigle C., Ferrara J.L., Antin J.H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 330:1994;100-106.
66. Storb R. Non-myeloablative preparative regimens: experimental data and clinical practice. Perry M. Educational Book of the 35th Annual Meeting of the American Society of Clinical Oncology. 1999;241-249 American Society of Clinical Oncology, Alexandria, VA.
67. Carlens S., Remberger M., Aschan J., Ringden O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant. 7:2001;31-38.
68. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine-analog containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 89:1997;4531-4536.
69. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 97:2001;631-637.
70. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
71. Carella A.M., Lerma E., Dejana A., et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regiment in patients with hematologic neoplasias. Hematologica. 83:1998;904-909.
72. Khouri I., Lee M.-S., Palmer L., et al. Transplant-lite using fludarabine-cyclophosphamide and allogeneic stem cell transplantation for low-grade lymphoma. Blood. 94:1999;1553a.
73. Plunkett W., Sanders P. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 49:1991;239-245.
74. Gandhi V., Estey E., Keating M.H., Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 11:1993;116-124.
75. Estey E., Plunkett W., Gandhi V., Rios M.B., Kantarjian H., Keating M.J. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 9:1993;343-350.
76. Keating M.J., O'Brien S., Robertson L.E., et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 14:(suppl 2):1994;11-16.
77. Niederwieser D., Maris M., Hegenbart U., et al. Allogeneic unrelated hematopoietic stem cell transplants (HSCT) after conditioning with 2 Gy total body irradiation (TBI), fludarabine (FLU) and a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) in patients ineligible for conventional transplants. Blood. 96:(suppl 1):2000;413a.
78. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 94:1999;3234-3241.
79. Nagler A., Slavin S., Varadi G., et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 25:2000;1021-1028.
80. Junghanss C., Marr K.A., Carter R.A., et al. Incidence of bacterial and fungal infections after nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 98:2001;479a.
81. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared to myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 99:2002;1978-1985.
82. Khouri I., Keating M., Korbling M., et al. Transplant lite: induction of graft-versus-leukemia using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16:1998;2817-2824.
83. Gharton G., Bjorkstrand B. Progress in hematopoietic stem cell transplantation for multiple myeloma. J Intern Med. 248:2002;185-201.
84. Giralt S.A., Weber D., Aleman A., et al. Nonmyeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma. Blood. 94:(suppl 1):1999;1549a.
85. Carella A.M., Cavaliere M., Lerma E., et al. Auto grafting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 18:2000;3918-3924.
86. Garban F., Attal M., Rossi J.F., et al. Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia. 15:2001;642-646.
87. Maloney D.G., Sahebi F., Stockerl-Goldstein K.E., et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood. 98:(suppl 1):2001;434a.
88. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 343:2000;750-758.
89. Rondon G., Giralt S., Huh Y., et al. Graft versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 18:1996;669-672.
90. Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 87:1996;1196-1198.
91. McSweeney P., Niederwieser D., Shizuru J., et al. Outpatient allografting with minimally myelosuppressive immunosuppressive conditioning of low-dose TBI and post grafting cyclosporine and mycophenolate mofetil. Blood. 94:(suppl 1):1999;393a.
92. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 96:2000;2419-2425.
93. Naparstek E., Or R., Nagler A., et al. T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 89:1995;506-515.
94. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science. 276:1997;1719-1724.
95. Smit W.M., Rijnbeek M., Van Bergen C.A.M., Willemze R., Falkenburg J.H.F. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant. 21:1998;553-560.
96. Mutis T., Verdijk R., Schrama E., Esendam B., Brnad A., Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 93:1999;2336-2341.